Phenibut (β-phenyl-γ-aminobutyric acid) dependence and management of withdrawal: Emerging nootropics of abuse

22Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This case report describes the development of withdrawal from phenibut, a gamma-aminobutyric acid-receptor type B agonist. Although phenibut is not an FDA-approved medication, it is available through online retailers as a nootropic supplement. There are reports of dependence in patients that misuse phenibut. We report a case in which a patient experienced withdrawal symptoms from phenibut and was successfully treated with a baclofen taper. This case report highlights the development of phenibut use disorder with coingestion of alcohol and potential management for phenibut withdrawal. We believe clinicians must be aware of how phenibut dependence may present and how to manage the withdrawal syndrome.

Cite

CITATION STYLE

APA

Ahuja, T., Mgbako, O., Katzman, C., & Grossman, A. (2018). Phenibut (β-phenyl-γ-aminobutyric acid) dependence and management of withdrawal: Emerging nootropics of abuse. Case Reports in Psychiatry, 2018. https://doi.org/10.1155/2018/9864285

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free